Product Description
Mycophenolate mofetil EP Pharmaceutical API Antiviral made in china 128794-94-5
AI Product Description
*The following content is generated by AI and is for reference only.
Mycophenolate mofetil (MMF) is a widely utilized immunosuppressive prodrug, primarily manufactured in China for global pharmaceutical markets under strict European Pharmacopoeia (EP) standards. Although frequently associated with antiviral research due to its mechanism of inhibiting viral replication in certain contexts, MMF is clinically designated as an antirejection agent rather than a direct antiviral drug. Its chemical identity is defined by the molecular formula C₂₃H₃₁NO₇ and the CAS number 128794-94-5. Structurally, it serves as the 2-morpholinoethyl ester of mycophenolic acid, designed to enhance oral bioavailability compared to its active parent compound.
Upon administration, MMF undergoes rapid hydrolysis in the gastrointestinal tract and liver to release mycophenolic acid, the pharmacologically active moiety. This active metabolite selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), a critical enzyme in the de novo synthesis of guanosine nucleotides. By blocking this pathway, MMF preferentially suppresses the proliferation of T and B lymphocytes, which rely heavily on de novo purine synthesis, while sparing cells that utilize salvage pathways. Consequently, it plays a pivotal role in preventing acute organ rejection in patients receiving renal, cardiac, or hepatic transplants. It is commonly prescribed as an adjunct therapy alongside cyclosporine and corticosteroids to improve graft survival rates.
The production of Mycophenolate mofetil EP API in China has established itself as a significant component of the global supply chain, adhering to rigorous quality control measures to ensure high purity and consistency. Manufacturers in China have invested heavily in advanced synthesis technologies to meet international regulatory requirements, including those set by the EMA and FDA. Beyond transplantation, ongoing clinical investigations explore its potential utility in treating autoimmune disorders such as lupus nephritis and dermatomyositis, leveraging its potent anti-proliferative properties. While not a first-line antiviral, its ability to modulate immune responses makes it relevant in managing viral reactivations in immunocompromised hosts. As a versatile therapeutic agent, MMF remains a cornerstone in modern transplant medicine, offering a favorable balance between efficacy and safety when managed correctly.